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SUMMARY AND CONCLUSIONS
Sepsis or septic shock is a serious l ife-threatening condition, which refers to a con-
stellation of clinical signs, such as fever (or hypothermia), chil ls, organ dysfunction,
hypotension or even shock, that suggest systemic infection. Recent evidence suggests
that this clinical syndrome associated with gram-negative bacteremia (or serious local
gram-negative infecticln) is most likely caused by endotoxin from the gram-negative
bacterial cell-wall. Although the endot<lxin molecules can induce a clinical syndrome
that is strikingly similar to septic shock, it has recently become clear that many of the
features of septic shock result from a complex cascade of endogenous mediators
triggered by the bacterial endotoxin.
It has been estimated that 10,000 -40,000 patients per year in the United States
alone may develop a nosocromial gram-negative sepsis. Studies in Europe revealed an
incidence of nosocomial infections of -r 5c/o. Of these nosocomial infections approxi-
mately 27a is caused by sepsis. In 198t3 in our country approximately 1.3 mill ion people
were admitted to hospital, it 5a/o of these patients develop a nosocomial infection and
of this -5ola pproximalely 2o/o is sepsis then 1300 patients per year will develop a noso-
comial sepsis. The mortality rate due to severe gram-negative infections and in particu-
lar those associated with shock, is sti l l  up to 50o/o in spite of appropriate antimicrobial
therapy and optimum supportive care. From the beginning of the antibiotic era it has
been suggested that in some circumstances shock might be precipitated by bacterial
cell lysis and the sudden release of endotoxin from gram-negative bacteria exposed to
antibiotics. The development and use of new and increasingly potent antibiotics did
not have a progressive impact on the survivnl rate of patients with gram-negative
sepsis. In this thesis we have studied the effects of several "new" antibiotics, generally
used in the management of patients with sepsis, on the release of endotoxin from
gram-negative bacteria in-vitro and in-vivo.
In chapter I a review of the epidemiologic, pathophysiologic, and clinical aspects of
gram-negative sepsis is given. We briefly discuss the clinical features and the patho-
physiologic mechanisms responsible for the profclund alterations in systemic vascular
resistance, myocardial contractility and cellular oxygen extraction, complement activa-
tion. pulmonary function, and coagulation disorders that are associated with gram-
negative sepsis in adults. The first principle for early diagnosis of gram-negative sepsis
is to maintain a high index of suspicion in a clinical setting that predisposes a patient
to sepsis. Once the diagnosis of gram-negative sepsis has been considered clinically, the
next step diagnostically and one of the most important steps therapeutically is to
identify the source of infection. S<lme of the diagnostic procedures, such as the Gram-




A major part of gram-negative sepsis develops secondary as a complication of
identif iable local infecti<)n -e.g. invasive infections of the urinary trÍ lct. intra-abdominal
infections, pulmonary infections, etc. Of the gram-negative bacteremias originating in
the community close to 20c/o-50clb have a urinary tract origin. We hzrve retrospectively
reviewed the overall data of significant bklod isolates derivecl from 520.1 patients from
our university hospital and twelve municipal h<lspitals in our region during the years.
1984-1989. Overall the commonest isolate was Escherichia coli (21.47o). E. c'oli, Stuplr
yktcoccus aLtreus antl StuphylococcLts epidermidis accounted tor 52a/o of bacteremias.
Almost 50o/o of the patients had a positive blo<ld culture with a gram-positive microor-
ganism. Finally, this chapter reviews the l iterature on the subject of antibiotic-induced
release of endotoxin and other mediators. l ike tumrlr necrosis factor (TNF) during the
treatment of grarn-negative infection. The mentioned studies on the role of endot<lxin
liberation in severe sepsis and/rlr meningitis both in animals and man inclicate that
endotoxin is l iberated after antibiotic treatment of severe gram-negative infection
(peritonitis, sepsis, meningitis), and that this increase mny be associated with mortality.
In chapter 2 we have reviewed the reports on TNF-alpha, IL-1 and IL-ó that have
contributed significantly to characterizing the cytokine netwrtrk in infectious disease,
and especially in septic shock. Macrophages (monocytes) appear to be the mclst
important cells responsible for endiltoxin-induced effects. Four important mediators
produced by macrophages (monocytes) after activation by endotoxin are tumur
necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), interleukin I
(lL-1) (predominantly IL-1Í.1), and interleukin ó (lL-6). TNF, also known as cachectin,
has been implicated as one of the most important host mediators involved in the
etioklgy of septic shock. IL-ó is attracting increasing attention for its role in modulating
both the acute phase and immunologic responses to infection. It has also been suggest-
ed that IL-6, either by itself or by interactions with TNF, tL-1 or LPS. is involved in
the pathogenesis of septic shock. It has also been demonstrated in an animal model clf
sepsis that interferon-gamma, in addition to TNF, also plays a role in the pathogenesis
of sepsis.
ln Chapter 3 the effects of different types and c<lmbinations of antimicr<lbial agents
tln endotoxin release from gram-negative bacteria in-vitro and in-vivo was studied. In
an in-vitro study using a E. coli culture, total end<ltoxin levels increased approximately
five-fold uptln incubation with ceftazidime, tobramycin or the combination of tobramy-
cin with cefuroxime, whereas incubation with cefuroxime or aztreonam alone caused
alate 22 and 49 fold increase in tcltal endotoxin, respectively, after rt hours. In chlor-
amphenicol treated cultures there was sti l l  an increase in viable counts during therapy,
resulting in an ultimately 7tt f<lld increase of mean levels of total end<ltoxin. Free
endotoxin levels increased approximately six-fold within t hour upon treatment with
imipenem, alone or in combination with t<lbramycin, or ceftazidime as the result of
rapid lysis tlf bacteria. Treatment with cefuroxime ilr aztreonernt induce<J a relativelv
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late hut much higher release of free endotoxin (l l t3 and 222f<tld, resp.), which was
due to the formation of long fi lamentous structures during the first 2 hours of incuba-
tion and eventually cell lysis. Both tobramycin and the combination of tobramycin with
cefuroxime caused a more gradual rise in free endotoxin, with a -r 15 fold increase in
free endotoxin at 4 hours. In chklramphenicol treated cultures, as in the control
cultures. the level of free endotoxin remained propclrtional to the amount of viable or-
ganisms. We also studied plasma endot<lxin levels in 20 patients with septic shock. Ten
out of these 20 patients had a detectable endotoxemia on admission. In three of these
patients we noticed a 2, 3 and 1-5 fold increase in plasma endotoxin (total) level,
respectively. after the start of antibiotic treatment. Of these 3 patients, 2 had a
positive blood culture with E. coli and Klebsiella pnewnonitte, resp. while the third
patient had negative blood cultures but had a Pseudomonastteruginosa infection of the
urinary tract. The data on the plasma levels of total, free, and cell-bound endotoxin in
two of these patients in relation to the administration of the antibiotics used are
shown. The rise in plasma end<ltoxin level in these two patients was accompanied by
a decrease in blood pressure and a rise in plasma lactate levels.
Chapter 4 describes the influence <lf antibiotic-induced release of endotoxin from in-
vitro cultured E. coli on tumor necrosis factor-a (TNF) production by human mono-
cytes. After 4 hrs of incubation all antibiotic treated cultures (high dose) induced a
similar rise in extra-cellular TNF pnrducticln when compared to the controls. However,
aÍter 21 hrs of incubation a dramatic rise in TNF production by the monocytes was
noticed in the cefuroxime and aztreonam treated cultures as compared to the ceftazidi-
me and imipenem treated cultures. The cefuroxime-induced release of TNF could be
reduced by ad<Iition of tobramycin. The same differences in TNF producticln were
noticed in cell-associated TNF. Dose-response curves did not demonstrate differences
in TNF production in aztreonam or imipenem treated cultures. However, for both
cefuroxime and ceftazidime treated cultures low dose treatment resulted in a signifi-
cant higher production of TNF. The differences in TNF production between these
antibiotics could be explained by the production of f i laments upon treatment with
cefuroxime, aztreonam and low dose ceftazidime resulting in late bacterial lysis with
in consequence high levels of endotoxin, whereas treatment with imipenem or high
dose ceftazidime resulted in the formation of spheroplasts with early lysis of the
bacteria which resulted in much lower levels of endotoxin.
The addition of taurolidine, an endotoxin-binding agent, to either imipenem oÍ
aztreonam treated cultures prevented a rise in TNF production, caused by a nearly
complete neutralization of the released endotoxin. Finally, we demonstrated that three
hour preincubation with interleukin 4 (lL-4) resulted in a decrease in TNF production
in both aztreonam and imipenem treated cultures.
Chapter 5 evaluates the role of different antibiotics in the release of endotoxin and
the production of interleukin 6 (lL-6) during the treatment of experimental E. coli sep-
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t ical peritonitis. We also studied the effect of taurolidine on the release of endotoxin
and IL-6. In rats treated with placebo or taurolidine, we demonstrated a correlation
between viable counts and the levels of free endotoxin and IL-6. Despite decreasing
levels of viable counts after treatment with ceftazidime, aztreonam or imipenem, levels
of free endotoxin increased in all animals. We did not notice any significant differenc-
es in the extent of endotoxin release between the different treatment groups. Howev-
er, we did find significant differences in the IL-6 pnrduction between the clifferent
treatment groups. After two h<lurs of treatment, IL-6 levels had increased in all
animals with the highest levels in the imipenem treated animals, whereafter IL-6 levels
decreased again in the rats treated with imipenem or ceftazidime, while in the rats
treated with placebo or aztreonam IL-ó levels further increased. The increase in IL-6
levels was associated with poor outcome. The increase in IL-6 levels in the aztreonam
treated animals is thought to be the result of the formation of long bacterial f i laments
in the abdominal cavity.
Treatment with taurolidine, akrne or in combination with aztreonam, could not
prevent or inhibit the release of endotoxin or IL-6, it rather caused an unexplained
dramatic increase in IL-6 levels, which was associated with an increased mortality. We
conclude that antibiotics can cause the release of endotoxin in spite of decreasing
levels of bacteremia. And we have demonstrated an antibiotic type-dependent increase
in plasma IL-6 levels. and also found an association between the level of IL-ó and
mortality.
In chapters 6 and 7 we describe the patterns of cytokines, plasma endotoxin,
plasminogen activator inhibitor (PAI), complement activation products and acute phase
proteins during the treatment of 20 consecutive patients with clinically defined sepsis.
Ten septic patients (50c/o) had detectable endotoxemia. Levels of TNF and IL-ó were
elevated ín 94o/o and l00o/o of the patients, respectively, and were clearly interrelated.
The septic patients showed significantly higher levels of TNF, IL-6, PAI, C-reactive
protein and serum amyloid-A compared to the non-septic patients.
Levels of complement C3a and C3d were elevatedin90a/o of the patients in com-
parison to 74o/o and 42a/o,respectively of 7 patients with non-septic shock. Plasma IL-6
levels, PAI levels and C3a levels correlated with the severity of illness and high C3a
levels were associated with fatal outcome. C3a was also correlated inversely with mean
arterial pressure. Levels of complement C3a and C3d significantly correlated with
levels of PAi and correlated inversely with antithrombin-Ill levels. After the start of
antibiotic treatment, high levels of TNF and PAI persisted in the nonsurvivors in
contrast to decreasing levels in most of the survivors. After an initial increase in 7
patients, IL-6 levels decreased in all septic patients also in nonsurvivors. Levels of C3a
and C3d did not decrease significantly during the first 24 hours of treatment. We














in the pathogenesis of septic shclck and may be involved in the development clf some
of the fatal complications like hypotension and disseminated intravascular coagulation.
In conclusion:
The amount and rate of release of endotoxin from gram-negative bacteria and the
induction of TNF by monocytes, during treatment in-vitro with different (combinations
of) antibiotics show large differences, even between the various B-lactam antibiotics
depending on their mode of action on the cell wall. It is suggested that in experimental
animals, treatment of gram-negative sepsis is associated with an antibiotic-type depen-
dent production of inflammatory mediators. An antibiotic-induced release of endotoxin
and/or clther mediators may be associated with a high mortality. Although the clinical
relevance of these differences remains to be investigated, we also conclude that
antibiotic-induced release of endotoxin from gram-negative bacteria may occur during
the treatment of adult human sepsis and that this rise in endotoxin levels may be
accompanied by alterations in hemodynamics. Pursuing the data presented here, it
might be possible to select an antibiotic treatment that effectively reduces the number
of viable bacteria while the release of endotoxin, both with respect to rate and ulti-
mate amount, is minimized. This might be an important avenue for the clinical im-
provement of antimicrobial therapy of severe gram-negative infections. Good clinical
studies are needed to compare the effects of the different antibiotics on the release of
endotoxin and other mediat<-rrs in relation to changes in hemodynamics and organ
failure during the treatment of human sepsis. However, one cannot expect more
effective treatment of gram-negative sepsis to result from still more potent antimicro-
bial therapy alone. Therapy should also be aimed at preventing the release of end<ltox-
in or neutralizing or removing liberated endotoxin (see chapter 8). Especially, the use
of monoclonal antibodies against endotoxin may substantially reduce mortality in a
subgroup of patients with sepsis or septic shock.
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